Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Hepatocellular 9Neoplasm Metastasis 5Stomach Neoplasms 4Biliary Tract Neoplasms 4Neoplasms 3Esophageal Squamous Cell Carcinoma 3Small Cell Lung Carcinoma 2Sarcoma 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Locally Advanced Rectal Cancer 2Hodgkin Disease 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Recurrence 1Plaque, Atherosclerotic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Overall Survival 1Osteosarcoma 1NSCLC 1

Interventions

dehydroftorafur 1Taxes 1Radiotherapy, Intensity-Modulated 1Radiation 1Platinum 1Paclitaxel 1Immune Checkpoint Inhibitors 1Fluorouracil 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Capecitabine 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Anal Canal Carcinoma × Immune Checkpoint Inhibitors × Clear all
NCT05374252 2022-05-16

Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 3 Unknown
102 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡